Related Experiment Videos
Clinical experience with carvedilol
1Yale University School of Medicine, New Haven, Connecticut.
Insights
Carvedilol, a beta-blocker, shows effectiveness as a once-daily monotherapy for hypertension in young and elderly patients. This well-tolerated drug offers simple titration and comparable response rates to other initial therapies.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertension management requires effective and well-tolerated antihypertensive agents.
- Beta-blockers with vasodilating properties represent a therapeutic option.
Purpose of the Study:
- To evaluate the efficacy of carvedilol as a once-daily monotherapy for hypertension.
- To assess the tolerability and response rates of carvedilol in diverse patient populations.
Main Methods:
- Clinical experience with carvedilol in hypertensive patients (young and elderly).
- Assessment of once-daily monotherapy efficacy and titration simplicity.
- Evaluation of patient tolerability and short-term metabolic effects.
Main Results:
- Carvedilol demonstrates effectiveness as a once-daily monotherapy for both young and elderly hypertensives.
- Simple dose titration leads to effective therapeutic levels.
- Response rates are comparable to other recommended monotherapeutic agents.
- The drug is generally well-tolerated with no significant short-term metabolic changes.
Conclusions:
- Carvedilol is a viable and effective once-daily monotherapy option for hypertension.
- Its favorable tolerability and simple titration profile support its use in clinical practice.
- Further research is warranted to establish long-term effectiveness.
Abstract:
Clinical experience indicates that carvedilol, a beta-blocker with vasodilating properties, is effective as once daily monotherapy in both young and elderly hypertensives. Titration is simple to an effective dosage, and response rates appear to be equivalent to those noted with other monotherapeutic agents presently recommended as initial therapy in hypertension. The drug is well tolerated by the majority of patients. No significant metabolic changes have been noted with carvedilol in short-term studies. Additional research is ongoing to determine the long-term effectiveness of this new antihypertensive agent.